…
Mach7 Technologies Limited develops and commercializes medical imaging and data management software solutions for healthcare organizations in North America, the Asia Pacific, the Middle East, Europe, and internationally. It offers eUnity enterprise diagnostic viewer, a zero-footprint viewer that allows medical professionals to remotely access patients' medical images; vendor-neutral archive (VNA), a vendor agnostic data management solution, which includes administration tools that allow for the storage, access, retrieval, and viewing of images across a healthcare network. Mach7 Technologies Limited was founded in 2007 and is headquartered in Melbourne, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
MACH7 Technologies Ltd provides enterprise imaging and medical data management software for hospitals and healthcare networks to ingest, store and distribute diagnostic images and related clinical information. Long-term growth drivers include healthcare digitization, migration to cloud-native enterprise imaging platforms and rising demand for interoperability and AI-enabled workflows, which could support recurring software and services revenue. The company appears positioned as a specialist vendor in a niche segment with potential to replace legacy systems and capture share as institutions modernize imaging infrastructure.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -9.44M | -7.96M | -9.75M | -6.66M | -6.33M |
| Net income | -8.93M | -6.20M | -7.97M | -1.05M | -4.17M |
| Selling general administrative | - | 4.70M | 26.96M | 27.40M | 23.81M |
| Selling and marketing expenses | - | 0.85M | 0.82M | 0.76M | 0.69M |
| Gross profit | -1.89M | 8.38M | -6.42M | 29.06M | 26.12M |
| Reconciled depreciation | - | - | 7.25M | 8.68M | 9.08M |
| Ebit | -7.72M | -7.98M | -22.34M | -17.17M | -6.28M |
| Ebitda | -1.18M | -7.06M | -15.09M | -8.49M | 2.80M |
| Depreciation and amortization | 6.54M | 0.91M | 7.25M | 8.68M | 9.08M |
| Operating income | -7.72M | -8.42M | -10.09M | -7.38M | -7.04M |
| Other operating expenses | 35.63M | 33.17M | 39.20M | 6.90M | 7.03M |
| Interest expense | 0.07M | 0.12M | 0.06M | 0.05M | 0.06M |
| Tax provision | - | -1.76M | -1.78M | -5.61M | -2.17M |
| Interest income | - | 0.29M | 0.89M | 0.71M | 0.70M |
| Net interest income | - | - | 0.82M | 0.33M | -0.03M |
| Income tax expense | -0.51M | 1.76M | -1.78M | -5.61M | -2.17M |
| Total revenue | 27.91M | 33.79M | 17.24M | 30.05M | 27.08M |
| Total operating expenses | 5.83M | 7.77M | 5.88M | 37.43M | 34.12M |
| Cost of revenue | 29.80M | 25.40M | 23.66M | 0.99M | 0.96M |
| Total other income expense net | -1.72M | 0.46M | 12.58M | 10.18M | 9.20M |
| Net income from continuing ops | - | - | -7.97M | -1.05M | -4.17M |
| Net income applicable to common shares | - | -6.20M | -7.97M | -1.05M | -4.17M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 50.50M | 64.21M | 73.03M | 82.31M | 78.92M |
| Intangible assets | 11.77M | 18.34M | - | 31.11M | 39.01M |
| Other current assets | 0.74M | 1.83M | 0.92M | 4.16M | 4.04M |
| Total liab | 15.93M | 18.63M | 21.17M | 22.82M | 20.55M |
| Total stockholder equity | 34.56M | 45.58M | 51.86M | 59.48M | 58.38M |
| Other current liab | 1.19M | 13.10M | 2.46M | 2.66M | 2.44M |
| Common stock | 114.02M | 114.00M | 116.24M | 115.70M | 115.30M |
| Capital stock | - | - | - | 115.70M | 115.30M |
| Retained earnings | -82.82M | -75.01M | -71.01M | -63.53M | -63.50M |
| Other liab | - | - | - | 7.00M | 9.02M |
| Good will | 3.91M | 4.28M | 4.19M | 4.35M | 4.30M |
| Other assets | - | - | - | 4.95M | 1.34M |
| Cash | 19.92M | 23.07M | 26.18M | 23.39M | 25.75M |
| Cash and equivalents | - | - | - | 16.08M | 18.32M |
| Total current liabilities | 14.38M | 14.41M | 15.09M | 14.83M | 10.39M |
| Current deferred revenue | 11.69M | - | 11.63M | 11.22M | 7.03M |
| Net debt | -19.84M | -21.95M | -24.91M | -22.19M | -24.42M |
| Short term debt | 0.07M | 0.22M | 0.18M | 0.21M | 0.19M |
| Short long term debt total | 0.08M | 1.12M | 1.27M | 1.20M | 1.33M |
| Other stockholder equity | - | - | - | -52.17M | -51.80M |
| Property plant equipment | - | - | - | 2.00M | 2.07M |
| Total current assets | 26.44M | 30.28M | 33.27M | 34.89M | 32.20M |
| Net tangible assets | - | - | - | 24.02M | 15.06M |
| Net receivables | 5.78M | 5.38M | 6.17M | 6.71M | 2.00M |
| Inventory | - | - | - | 0.63M | 0.42M |
| Accounts payable | 1.44M | 1.09M | 0.82M | 0.74M | 0.72M |
| Accumulated other comprehensive income | 3.36M | 6.59M | 6.62M | 7.31M | 6.58M |
| Non currrent assets other | 1.53M | 5.00M | 25.02M | 5.80M | 0.76M |
| Non current assets total | 24.06M | 33.93M | 39.76M | 47.42M | 46.72M |
| Capital lease obligations | - | - | - | 1.20M | 1.33M |
| Long term debt total | - | - | - | 0.99M | 1.14M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | - | -0.39M | -0.36M | -0.44M |
| Change to liabilities | - | - | - | 4.42M | 2.97M |
| Total cashflows from investing activities | -0.92M | -1.70M | -0.39M | -0.36M | -0.44M |
| Net borrowings | - | - | - | -0.25M | -0.41M |
| Total cash from financing activities | -0.16M | -2.43M | -0.03M | -0.07M | 0.55M |
| Change to operating activities | - | - | - | -5.45M | -0.55M |
| Net income | -8.93M | -6.20M | -7.97M | -1.05M | -4.17M |
| Change in cash | -3.15M | -3.11M | 2.78M | -2.35M | 24.85M |
| Begin period cash flow | 23.07M | 26.18M | 23.39M | 25.75M | 0.90M |
| End period cash flow | 19.92M | 23.07M | 26.18M | 23.39M | 25.75M |
| Total cash from operating activities | -1.26M | 0.87M | 3.45M | -2.61M | 6.37M |
| Issuance of capital stock | - | - | 0.19M | 0.19M | 0.96M |
| Depreciation | 6.54M | 7.24M | 7.25M | 1.17M | 1.31M |
| Other cashflows from investing activities | - | -0.94M | -0.24M | - | 0.00M |
| Change to inventory | - | - | - | 1.03M | -2.42M |
| Change to account receivables | 0.40M | 1.08M | 3.13M | -4.63M | 0.08M |
| Sale purchase of stock | -0.00M | -2.24M | - | 0.19M | 0.96M |
| Other cashflows from financing activities | -0.18M | - | -0.22M | -0.25M | -0.41M |
| Change to netincome | - | - | - | -4.59M | -1.03M |
| Capital expenditures | 0.07M | 0.76M | 0.15M | 0.36M | 0.44M |
| Change in working capital | 0.80M | 0.88M | 4.22M | -4.63M | 0.08M |
| Stock based compensation | - | 1.11M | 1.27M | 1.08M | 1.70M |
| Other non cash items | 0.32M | -2.16M | -1.32M | -2.74M | 9.23M |
| Free cash flow | -1.33M | 0.11M | 3.30M | -2.97M | 5.94M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| M7T MACH7 Technologies Ltd |
- -% |
0.26 | - | 11.15 | 2.19 | 1.77 | 2.53 | 41.71 |
| PME Pro Medicus Ltd |
-3.10 1.49% |
205.13 | 81.98 | 106.38 | 83.13 | 43.70 | 74.38 | 95.34 |
| 4DX 4DMEDICAL Ltd |
-0.13 5.39% |
2.28 | - | - | 205.57 | 8.53 | 170.03 | -7.29 |
| CGS Cogstate Ltd |
-0.09 2.66% |
3.29 | 33.80 | 27.86 | 9.59 | 6.95 | 6.35 | 19.27 |
| AYA ARTRYA Ltd |
- -% |
3.50 | - | - | 20505.14 | 7.00 | 16927.51 | 0.33 |
Mach7 Technologies Limited develops and commercializes medical imaging and data management software solutions for healthcare organizations in North America, the Asia Pacific, the Middle East, Europe, and internationally. It offers eUnity enterprise diagnostic viewer, a zero-footprint viewer that allows medical professionals to remotely access patients' medical images; vendor-neutral archive (VNA), a vendor agnostic data management solution, which includes administration tools that allow for the storage, access, retrieval, and viewing of images across a healthcare network. Mach7 Technologies Limited was founded in 2007 and is headquartered in Melbourne, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael Lampron | CEO, MD & Director | NA |
| Mr. Steven Parkes | Global Chief Financial Officer | NA |
| Rebecca Thompson | Head of Investor Relations | NA |
| Mr. Bob Tranchida | VP of Marketing | NA |
| Mr. David Madaffri | Exec. VP | NA |
| Ms. Veronique Morgan-Smith | Company Sec. | NA |
| Mr. David Madaffri | Chief Operating Officer | NA |
| Francoise Dixon | Head of Investor Relations | NA |
| Mr. Bob Tranchida | Vice President of Marketing | NA |
| Ms. Dyan O'Herne | Chief Financial Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.